Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest Romidepsin Stories

2014-02-26 23:22:59

The global market for histone deacetylase inhibitors (HDIs) was valued at $223.2 million in 2012 and was estimated at $361.8 million for 2013. BCC Research expects the market to grow to $954.3 million by 2018, and register a five-year compound annual growth rate of 21.4% from 2013 to 2018. Wellesley, Mass. (PRWEB) February 26, 2014 According to a new technical market research report Histone Deacetylase Inhibitors: Emerging Markets, from BCC Research (http://www.bccresearch.com), the...

2013-12-11 13:14:42

A drug now used to treat a type of lymphoma has shown surprising benefit in preclinical studies of inflammatory breast cancer, according to a researcher at Thomas Jefferson University’s Kimmel Cancer Center. The finding, published in the October issue of the Journal of Experimental Therapeutics and Oncology, has led to development of a phase 1/2 clinical trial at Kimmel Cancer Center to test the agent, Romidepsin (Istodax™), in combination with nab-paclitaxel (Abraxane™) chemotherapy...

2013-04-16 12:26:45

SHENZHEN, China, April 16, 2013 /PRNewswire/ -- Chipscreen Biosciences, a leading integrated Chinese biotech company specialized in discovery and development of novel small molecule pharmaceuticals with a primary focus in oncology, metabolic disease, and autoimmune diseases, today announced the achievement of the primary endpoint in the pivotal, registrational Phase 2 CHIPEL trial of Chidamide (Epidaza(®)), an orally active benzamide type of class I-selective histone deacetylase...

2008-06-17 09:00:08

Gloucester Pharmaceuticals today announced that positive data from a Phase 2 trial of romidepsin conducted by the U.S. National Cancer Institute (NCI) were presented at the 13th Congress of the European Hematology Association in Copenhagen, Denmark. Romidepsin is a novel, cyclic peptide, pan-HDAC inhibitor under investigation for hematologic malignancies. In a presentation entitled Romidepsin Induces Clinically Significant and Durable Responses in Relapsed or Refractory CTCL: A National...